Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artelo BiosciencesARTL +1.71%27 Cash-to-Debt is 14.29 as of Mar. 2026, which is 97% below its 10-year median of 427.65. GuruFocus rates ARTL with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, Artelo Biosciences ranks better than 58.21% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Artelo Biosciences's cash to debt ratio for the quarter that ended in Mar. 2026 was 14.29.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Artelo Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Artelo Biosciences's Cash-to-Debt or its related term are showing as below:
ARTL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: 427.65 Max: No Debt
Current: 14.29
During the past 12 years, Artelo Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.37. And the median was 427.65.
ARTL's Cash-to-Debt is ranked better than 58.21% of 1400
companies
in the Biotechnology industry
Industry Median: 6.57
vs ARTL: 14.29
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Artelo Biosciences Cash-to-Debt Related Terms
Artelo Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Artelo Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (ARTL) has a Cash-to-Debt of 14.29 as of Mar. 2026. This is 97% below median its historical median of 427.65. Over the past decade, Artelo Biosciences' Cash-to-Debt has ranged from 0.37 to 10,000.00. According to the industry distribution chart, Artelo Biosciences ranks #585 out of 1400 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Artelo Biosciences' Cash-to-Debt too high?
Artelo Biosciences' current Cash-to-Debt of 14.29 is 97% below median its 10-year median of 427.65. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.57. Artelo Biosciences' value of 14.29 is 117.5% above this industry median. Based on the distribution chart, Artelo Biosciences ranks #585 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Cash-to-Debt compare to ADTX and GOVX?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #585 out of 1400 companies for Cash-to-Debt. This puts Artelo Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 6.57. Artelo Biosciences' value of 14.29 is 117.5% above this benchmark. Historically, Artelo Biosciences' own Cash-to-Debt has ranged from 0.37 to 10,000.00 over the past decade. While the company's 10-year median is 427.65 vs. the industry median of 6.57, Artelo Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.57, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current Cash-to-Debt of 14.29 is 117.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current Cash-to-Debt is 14.29, which is 97% below median its own 10-year median of 427.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Cash-to-Debt of 14.29. The current Cash-to-Debt is 14.29, which is 97% below median its 10-year median of 427.65 and 117.5% above the Biotechnology industry median of 6.57. Artelo Biosciences' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Cash-to-Debt is 14.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
27GF Score
Get the complete analysis for ARTL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
